Market conditions continue to pose challenges for startups trying to raise money. Some of these companies might be a fit for Sanofi’s corporate venture capital arm, which the pharmaceutical giant has infused with a fresh $625 million to invest .

With the new capital commitment, Sanofi said Sanofi Ventures will remain focused on the pharma company’s key therapeutic areas: immunology, rare diseases, neurology, and vaccines. This year to date, Sanofi Ventures’ investments include participation in financing rounds for RNA interference therapies developer Atalanta Therapeutics , rare disease startup Glycomine , and neuroscience biotech Drain Therapeutics .

“By strengthening our investment capabilities, we are accelerating our ability to bring next-generation therapies that improve peo

See Full Page